[HTML][HTML] LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma
Radioresistance is the main obstacle in the clinical management of nasopharyngeal
carcinoma (NPC). linc00312 is deregulated in a number of human cancers, including NPC …
carcinoma (NPC). linc00312 is deregulated in a number of human cancers, including NPC …
[HTML][HTML] Selective activator of human ClpP triggers cell cycle arrest to inhibit lung squamous cell carcinoma
LL Zhou, T Zhang, Y Xue, C Yue, Y Pan… - Nature …, 2023 - nature.com
Chemo-activation of mitochondrial ClpP exhibits promising anticancer properties. However,
we are currently unaware of any studies using selective and potent ClpP activators in lung …
we are currently unaware of any studies using selective and potent ClpP activators in lung …
Genotoxic therapy and resistance mechanism in gliomas
Glioma is one of the most common and lethal brain tumors. Surgical resection followed by
radiotherapy plus chemotherapy is the current standard of care for patients with glioma. The …
radiotherapy plus chemotherapy is the current standard of care for patients with glioma. The …
[HTML][HTML] Therapeutic targeting of DNA damage response in cancer
W Choi, ES Lee - International journal of molecular sciences, 2022 - mdpi.com
DNA damage response (DDR) is critical to ensure genome stability, and defects in this
signaling pathway are highly associated with carcinogenesis and tumor progression …
signaling pathway are highly associated with carcinogenesis and tumor progression …
[HTML][HTML] Development of synthetic lethality in cancer: molecular and cellular classification
S Li, W Topatana, S Juengpanich, J Cao, J Hu… - … and Targeted Therapy, 2020 - nature.com
Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic
lethality provides a new approach for the treatment of mutated genes that were previously …
lethality provides a new approach for the treatment of mutated genes that were previously …
[HTML][HTML] ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization
ATRX, a chromatin remodeler protein, is recurrently mutated in H3F3A-mutant pediatric
glioblastoma (GBM) and isocitrate dehydrogenase (IDH)-mutant grade 2/3 adult glioma …
glioblastoma (GBM) and isocitrate dehydrogenase (IDH)-mutant grade 2/3 adult glioma …
[HTML][HTML] T cell-mediated additive cytotoxicity–death by multiple bullets
B Weigelin, P Friedl - Trends in cancer, 2022 - cell.com
Immune effector cells, including cytotoxic T cells (CTLs), induce apoptosis and eliminate
target cells by direct cell–cell contacts. In vivo, CTLs fail to efficiently kill solid tumor cells by …
target cells by direct cell–cell contacts. In vivo, CTLs fail to efficiently kill solid tumor cells by …
[HTML][HTML] Ionizing radiation triggers mitophagy to enhance DNA damage in cancer cells
Y Ren, P Yang, C Li, W Wang, T Zhang, J Li, H Li… - Cell Death …, 2023 - nature.com
Radiotherapy is an important cancer treatment strategy that causes DNA damage in tumor
cells either directly or indirectly. Autophagy is a physiological process linked to DNA …
cells either directly or indirectly. Autophagy is a physiological process linked to DNA …
[HTML][HTML] Targeting DNA damage response in prostate and breast cancer
AM Wengner, A Scholz, B Haendler - International journal of molecular …, 2020 - mdpi.com
Steroid hormone signaling induces vast gene expression programs which necessitate the
local formation of transcription factories at regulatory regions and large-scale alterations of …
local formation of transcription factories at regulatory regions and large-scale alterations of …
[HTML][HTML] The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …
years, with immunotherapies and targeted therapies having had minimal impact. Here, we …